Phase II Study of RC48-ADC in Treating Patients With Salivary Gland Tumors Expressing HER2
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about the efficacy and safety of RC48-ADC, a
HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low
expressing advanced or metastatic salivary cancer.